Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Compugen Ltd. - Ordinary Shares (NQ:CGEN)

2.055 -0.015 (-0.72%)
Delayed Quote Updated: 12:30 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Compugen Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets ↗
Compugen (NASDAQ:CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into tumor-associated... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Compugen (CGEN) Q2 2026 Earnings Call Transcript ↗
COM701 interim data expected in Q1 2027 as cash runway extends into 2029. 
Via The Motley Fool
Topics Earnings
News headline image
Compugen Q2 Earnings Call Highlights ↗
Compugen (NASDAQ:CGEN) said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash... 
Via MarketBeat
Topics Earnings
Compugen Ltd. (NASDAQ:CGEN) Q1 2026 Earnings Beat Sparks 12.73% Pre-Market Rally Amid Clinical Pipeline Progress ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Earnings Preview For Compugen ↗
 
Via Benzinga
News headline image
Compugen Q1 Earnings Call Highlights ↗
Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company... 
Via MarketBeat
Topics Earnings
News headline image
Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗
Compugen (CGEN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Compugen Ltd (NASDAQ:CGEN) Reports Q3 2025 Earnings Beat, Stock Rises ↗
Compugen (CGEN) Q3 2025 earnings beat estimates, with revenue up 26% and a narrower EPS loss. The stock surged 3.7% pre-market on the strong results. 
Via Chartmill
Topics Earnings
News headline image
Q3 Virtual Investor Summit: On-Demand Presentations Now Available
Via ACCESS Newswire
News headline image
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free
Via ACCESS Newswire
News headline image
Compugen Ltd (NASDAQ:CGEN) Reports Q2 2025 Revenue and EPS Miss, Shares Drop in Premarket ↗
Compugen Ltd (CGEN) misses Q2 2025 revenue and EPS estimates, shares drop 2% premarket. Weak financials and clinical progress concerns weigh on investor sentiment. 
Via Chartmill
News headline image
Earnings Scheduled For May 19, 2025 ↗
 
Via Benzinga
News headline image
Uncovering Potential: Compugen's Earnings Preview ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 4, 2025 ↗
 
Via Benzinga
News headline image
CGEN Stock Earnings: Compugen Beats EPS, Beats Revenue for Q2 2024 ↗
CGEN stock results show that Compugen beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
CGEN Stock Earnings: Compugen Misses EPS, Misses Revenue for Q1 2024 ↗
CGEN stock results show that Compugen missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
CGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023 ↗
CGEN stock results show that Compugen missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
7 Speculative Stocks to Double Your Money THIS Year ↗
Although terribly risky, these stocks to double your money could be enticing if you have some pocket change lying around. 
Via InvestorPlace
News headline image
Crude Oil Rises Over 1%; Biodexa Pharmaceuticals Shares Plunge ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 200 points on Tuesday. The Dow traded up 0.53% to 37,505.25 while the NASDAQ rose 0.51% to 14,980.71. The... 
Via Benzinga
Topics Stocks
News headline image
Earnings Scheduled For March 5, 2024 ↗
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. 
Via Benzinga
News headline image
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy... 
Via Benzinga
News headline image
Dow Jumps 150 Points; FactSet Shares Rise After Q1 Results ↗
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.46% to 37,476.21 while the NASDAQ rose 0.41% to 14,966.74. The S&P 500 also... 
Via Benzinga
Topics Stocks
Compugen Ltd. (NASDAQ: CGEN) is One of Tuesday Morning’s Most Active Stocks
Via Investor Brand Network
News headline image
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? ↗
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the  
Via Benzinga
News headline image
Why Are Stocks Up Today? ↗
Stocks are up today and investors wondering why will want to keep reading as we have a breakdown of the market's rally on Tuesday! 
Via InvestorPlace
News headline image
Why Is Compugen (CGEN) Stock Up 189% Today? ↗
Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences. 
Via InvestorPlace
News headline image
US Stocks Higher; Accenture Issues Weak Sales Outlook ↗
U.S. stocks traded higher this morning, with the Dow Jones index gaining around more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.17% to 37,369.84 while the... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.